BlackRock Ultra Short-Term Bond ETF (BATS: ICSH)

Latest news for BlackRock Ultra Short-Term Bond ETF (BATS:ICSH)

BlackRock Ultra Short-Term Bond ETF

iShares Liquidity Income ETF

The fund seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets in a portfolio of U.S. dollar-denominated investment-grade fixed- and floating-rate debt securities that are rated BBB- or higher by S&P Global Ratings and/or Fitch Ratings, Inc. (Fitch), or Baa3 or higher by Moodys Investors Service, Inc. (Moodys), or, if unrated, determined by BFA to be of equivalent quality.

Long Ideas

News

Bonds

Dividends

Specialty ETFs

Small Cap

Treasuries

Markets

Trading Ideas

ETFs

ICSH

VCLT

Unlike government bonds, corporate bonds have one major advantage: they offer strong returns.

Long-Term Vs. Short-Term: Which Of These Monthly-Paying Corporate Bond ETFs Is Right For You?

SXTP

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

SXTPW

JP Morgan analyst David Karnovsky maintains TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) with a Overweight and raises the price target from $126 to $132.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on TKO Group Holdings, Raises Price Target to $132

JP Morgan analyst Peter Peng maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Overweight and lowers the price target from $120 to $100.

SYNA

JP Morgan Maintains Overweight on Synaptics, Lowers Price Target to $100

JP Morgan analyst Andrea Teixeira maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Overweight and raises the price target from $80 to $97.

JP Morgan Maintains Overweight on SharkNinja, Raises Price Target to $97

JP Morgan analyst Paul Coster maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $27 to $22.

ARRY

JP Morgan Maintains Overweight on Array Technologies, Lowers Price Target to $22

JP Morgan analyst Philip Cusick maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Neutral and lowers the price target from $10 to $8.

JP Morgan Maintains Neutral on Warner Bros. Discovery, Lowers Price Target to $8

JP Morgan analyst Andrea Teixeira maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Overweight and lowers the price target from $224 to $207.

JP Morgan Maintains Overweight on e.l.f. Beauty, Lowers Price Target to $207

JP Morgan analyst Ryan Lambert downgrades Hilton Grand Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGV#NYSE">HGV</a>) from Overweight to Neutral and lowers the price target from $55 to $36.

Downgrades

JP Morgan Downgrades Hilton Grand Vacations to Neutral, Lowers Price Target to $36

Citigroup analyst Paul Diamond maintains Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) with a Buy and lowers the price target from $20 to $18.

Citigroup Maintains Buy on Permian Resources, Lowers Price Target to $18

Citigroup analyst Drew Foster maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and lowers the price target from $699 to $629.

HUBS

Citigroup Maintains Buy on HubSpot, Lowers Price Target to $629

Citigroup analyst Fatima Boolani maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and raises the price target from $305 to $310.

CYBR

Citigroup Maintains Buy on CyberArk Software, Raises Price Target to $310

Citigroup analyst Ygal Arounian maintains Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) with a Neutral and lowers the price target from $52 to $47.

Citigroup Maintains Neutral on Ziff Davis, Lowers Price Target to $47

Citigroup analyst Jon Tower maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Neutral and raises the price target from $30 to $32.

Citigroup Maintains Neutral on Sweetgreen, Raises Price Target to $32

Citigroup analyst Ygal Arounian maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and raises the price target from $112 to $115.

Citigroup Maintains Buy on Trade Desk, Raises Price Target to $115

Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Buy and raises the price target from $7 to $8.

ALLO

Citigroup Maintains Buy on Allogene Therapeutics, Raises Price Target to $8

Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $140 to $145.

EXPE

Citigroup Maintains Neutral on Expedia Group, Raises Price Target to $145

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Buy and lowers the price target from $11 to $10.

GDRX

Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $10

Citigroup analyst James Hardiman maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Buy and lowers the price target from $64 to $61.

Citigroup Maintains Buy on Six Flags Entertainment, Lowers Price Target to $61

Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $27 to $31.

CPRX

Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31

A Case For Getting Off The Sidelines And Into Bond ETFs